Clinical Trial Update: Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a fourth-generation CAR-T cell therapy targeting BCMA and CD19 for refractory systemic lupus erythematosus and lupus nephr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• BCMA/CD19 dual-target CAR-T cells (fourth-generation)

Snippet

Sponsor: Essen Biotech | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1, Phase 2 | Status: RECRUITING